Neomycin and Polymyxin B Sulfates and Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment is indicated for the treatment of superficial bacterial infections of the eyelid and conjunctiva in dogs and cats when due to organisms susceptible to the antibiotics contained in the ointment and where an anti-inflammatory is desired.
The three antibiotics present in Bacitracin-Neomycin-Polymyxin HC veterinary ophthalmic ointment provide a broad spectrum of activity against the gram-positive and gram-negative bacteria commonly involved in superficial infections of the eyelid and conjunctiva.
Hydrocortisone acetate exerts a marked anti-inflammatory action at the tissue level and effectively suppresses inflammation in many disorders of the anterior segment of the eye. Local application to the eye often gives rapid relief of pain and photophobia, particularly in lesions of the cornea.
The combined anti-inflammatory and antimicrobial activity of Bacitracin-Neomycin-Polymyxin-Hydrocortisone Acetate 1% Veterinary Ophthalmic Ointment permits effective management of many disorders of the anterior segment of the eye in which combined activity is needed.
Doasage & Administration: Apply a thin film over the cornea three or four times daily in dogs and cats. The area should be properly cleansed prior to the use of bacitracin-neomycin-polymyxin-HC veterinary ophthalmic ointment. Foreign bodies, crusted exudates, and debris should be carefully removed.
Contraindications: Ophthalmic preparations containing corticosteroids are contraindicated in the treatment of those deep, ulcerative lesions of the cornea where the inner layer (endothelium) is involved, in fungal infections and in the presence of viral infections.
Description: Each gram contains Bacitracin Zinc 400 units, Neomycin Sulfate 5 mg (equivalent to 3.5 mg of Neomycin Base), Polymyxin B Sulfate 10,000 units, Hydrocortisone Acetate 10 mg (1%), in a base of White Petrolatum and Mineral Oil.
Precautions: Sensitivity to this ophthalmic ointment is rare, however, if a reaction occurs, discontinue use of the preparation.
The prolonged use of antibiotic-containing preparations may result in overgrowth of nonsusceptible organisms including fungi. Appropriate measures should be taken if this occurs. If infection does not respond to treatment in two or three days, the diagnosis and therapy should be reevaluated. Animals under treatment with this product should be observed for usual signs of corticosteroid overdose which include polydipsia, polyuria and occasionally an increase in weight.
Use of corticosteroids, depending on dose, duration, and specific steroid, may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapidly acting corticosteroid should be considered in unusually stressful situations. Care should be taken not to contaminate the applicator tip during administration of the preparation.
Care should be taken not to contaminate the applicator tip of the tube during application of the preparation. Do not allow the applicator tip to come in contact with any tissue.
Adverse Reactions: Itching, burning or inflammation may occur in animals sensitive to the product. Discontinue use in such cases. SAP and SGPT (ALT) enzyme elevations, polydipsia and polyuria have occurred following parenteral or systemic use of synthetic corticosteroids in dogs. Vomiting and diarrhea (occasionally bloody) have been observed in dogs.
Cushings syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.
Federal law restricts this drug to use by or on the order of a licensed veterinarian
Warning: All topical ophthalmic preparations containing corticosteroids with or without an antimicrobial agent, are contraindicated in the initial treatment of corneal ulcers. They should not be used until the infection is under control and corneal regeneration is well under way. Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.
Additionally corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in cleft palate in offspring. Corticosteroids administered to dogs during pregnancy have also resulted in other congenital anomalies, including deformed forelegs, phocomelia, and anasarca.